431 related articles for article (PubMed ID: 18692691)
1. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
2. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
4. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M; Yohe S; Weisdorf D; Ustun C
Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
[TBL] [Abstract][Full Text] [Related]
5. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Marcucci G; Caligiuri MA; Bloomfield CD
Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature.
Huang L; Abruzzo LV; Valbuena JR; Medeiros LJ; Lin P
Am J Clin Pathol; 2006 Feb; 125(2):267-72. PubMed ID: 16393685
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
11. "Acute myelogenous leukemia like" translocations in CML blast crisis: two new cases of inv(16)/t(16;16) and a review of the literature.
Patel BB; Mohamed AN; Schiffer CA
Leuk Res; 2006 Feb; 30(2):225-32. PubMed ID: 16076492
[TBL] [Abstract][Full Text] [Related]
12. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
13. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
Estey E; Trujillo JM; Cork A; O'Brien S; Beran M; Kantarjian H; Keating M; Freireich EJ; Stass S
Hematol Pathol; 1992; 6(1):43-8. PubMed ID: 1601822
[TBL] [Abstract][Full Text] [Related]
14. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
Marcucci G; Caligiuri MA; Bloomfield CD
Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
[TBL] [Abstract][Full Text] [Related]
15. Dual color FISH on CBF primary acute myeloid leukemia.
Sorour A; Nafea D
Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
[TBL] [Abstract][Full Text] [Related]
16. Core binding factor acute myeloid leukemia (CBF-AML) in México: a single institution experience.
Ruiz-Delgado GJ; Macías-Gallardo J; Lutz-Presno J; Garcés-Eisele J; Hernández-Arizpe A; Montes-Montiel M; Ruiz-Argüelles GJ
Rev Invest Clin; 2011; 63(1):25-30. PubMed ID: 21574542
[TBL] [Abstract][Full Text] [Related]
17. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].
Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240
[TBL] [Abstract][Full Text] [Related]
18. Trisomy 22 as the sole abnormality is an important marker for the diagnosis of acute myeloid leukemia with inversion 16.
Xu W; Zhou HF; Fan L; Qian SX; Chen LJ; Qiu HR; Zhang SJ; Li JY
Onkologie; 2008 Sep; 31(8-9):440-4. PubMed ID: 18787351
[TBL] [Abstract][Full Text] [Related]
19. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]